Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease

Abstract EN

High-density lipoprotein (HDL) is a lipid and protein complex that consists of apolipoproteins and lower level HDL-associated enzymes.

HDL dysfunction is a factor in atherosclerosis and decreases patient survival.

Mass spectrometry- (MS-) based proteomics provides a high throughput approach for analyzing the composition and modifications of complex HDL proteins in diseases.

HDL can be separated according to size, surface charge, electronegativity, or apoprotein composition.

MS-based proteomics on subfractionated HDL then allows investigation of lipoprotein roles in diseases.

Herein, we review recent developments in MS-based quantitative proteomic techniques, HDL proteomics and lipoprotein modifications in diseases, and HDL subfractionation studies.

We also discuss future directions and perspectives in MS-based proteomics on HDL.